Abstract
Objective To observe the clinical efficacy and adverse reactions of raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment. Methods A total of 42 patients with advanced colorectal cancer were treated with raltitrexed containing regimen. The objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS) and adverse reactions were evaluated. Results The ORR of the 42 patients was 16.67%, DCR was 80.96%, and mPFS was 4.90 months (95%CI: 2.99-6.81 months). The most of adverse reactions were gradeⅠ-Ⅱ, including leucopenia (30.95%), thrombocytopenia (2.38%), anemia (40.48%), nausea and vomiting (2.38%), anorexia (4.76%), diarrhea (2.38%), transaminase elevation (47.62%) and fatigue (11.90%). Grade Ⅲ-Ⅳ transaminase elevation was found in only 4.76% of patients. Conclusion Raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment is effective and well tolerated, and further clinical application is recommended. Key words: Colorectal neoplasms; Drug therapy; Raltitrexed
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
